Search results for "Stromal tumours"
showing 4 items of 4 documents
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
2017
Background: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that mainly occurs within the first cycles of therapy, and dose and schedule adjustments are often required to reduce the frequency or severity of adverse events and to avoid early treatment discontinuation. To date, large amounts of data on the use of REG in metastatic GIST patients in daily clinical practice are not available, and we lack information about how this treatment personalization really a…
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, mu…
2013
Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rando…
Tumor del estroma gastrointestinal y schwannoma gástricos: una presentación inusual en un paciente sin neurofibromatosis
2020
The majority of gastric neoplasms are of epithelial type. Stromal tumours are the next most frequent and are most commonly gastrointestinal stromal tumours, followed by leiomyoma and schwannoma. We present an exceptional case of a patient with a gastrointestinal stromal tumour with suspicion of residual gastric disease, which was diagnosed post-operatively as a schwannoma.
I tumori stromali gastrointestinali: presentazione di sei casi e revisione della letteratura
2005
Gastrointestinal stromal tumours (GISTs) represent the most common kind of mesenchymal tumours that arise from the alimentary tract. GISTs express a growth factor receptor with tyrosine kinase function, which causes cellular proliferation and resistance to apoptosis. GISTs are generally found in the stomach (40-70%), and less commonly in the small intestine, colon-rectum, esophagus and peritoneum. Clinical and instrumental diagnosis is still very difficult to make. Surgery remains the standard treatment for nonmetastatic tumours. For non resectable and metastatic tumours seems to be effective the therapy with Imatinib mesylate, a specific inhibitor of tyrosine kinase receptor (KIT). Are ong…